A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma

Journal of Thoracic Oncology

Volumn 5, Issue 10, 2010, Pages 1692-1703

  Cao, Christopher Q ^a,b   Yan, Tristan D ^a,b   Bannon, Paul G ^a,b   McCaughan, Brian C ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b Baird Institute for Applied Heart and Lung Surgical Research   (Australia)

Author keywords

Extrapleural pneumonectomy; Malignant pleural mesothelioma; Systematic review

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CHLORINE DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; META TETRAHYDROXYPHENYLCHLORIN; METHOTREXATE; NAVELBINE; PACLITAXEL; PEMETREXED; RALTITREXED; UNCLASSIFIED DRUG; VINBLASTINE;

ADD ON THERAPY; ADJUVANT THERAPY; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CANCER MORTALITY; CANCER SURGERY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPLEURAL PNEUMONECTOMY; HUMAN; HYPERTHERMIC THERAPY; LUNG RESECTION; MALIGNAL PLEURAL MESOTHELIOMA; MALIGNANT MENINGIOMA; MALIGNANT MESOTHELIOMA; MALIGNANT PLEURAL MESOTHELIOMA; MORBIDITY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PERIOPERATIVE PERIOD; PHOTODYNAMIC THERAPY; PLEURA MESOTHELIOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; SURGICAL MORTALITY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR LOCALIZATION;

EID: 77958173270     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ed0489     Document Type: Article

References (74)

1. Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989;7:1157-1168. (Pubitemid 19196542)
2. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: 2636-2644. (Pubitemid 46606305)
3. Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer 1999;79:666-672. (Pubitemid 29046253)
4. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997;145:211-218. (Pubitemid 27057172)
5. Clements M, Berry G, Shi J, et al. Projected mesothelioma incidence in men in New South Wales. Occup Environ Med 2007;64:747-752. (Pubitemid 350044088)
6. Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:3007-3013.
7. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135:620-626.
8. Flores RM, Routledge T, Seshan VE, et al. The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer Staging System. J Thorac Cardiovasc Surg 2008;136:605-610.
9. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007;2:957-965. (Pubitemid 47511601)
10. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122: 788-795. (Pubitemid 33590380)
11. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999;68:1799-1804.
12. Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1996;111:815-825. (Pubitemid 26118862)
13. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group Trial. J Thorac Cardiovasc Surg 1991;102:1-9.
14. Zellos L, Richards WG, Capalbo L, et al. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2009;137:453-458.
15. Tilleman TR, Richards WG, Zellos L, et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg 2009;138:405-411.
16. Neragi-Miandoab S, Weiner S, Sugarbaker DJ. Incidence of atrial fibrillation after extrapleural pneumonectomy vs. pleurectomy in patients with malignant pleural mesothelioma. Interact Cardiovasc Thorac Surg 2008;7:1039-1042.
17. Allen AM, Den R, Wong JS, et al. Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy. Int J Radiat Oncol Biol Phys 2007;68:1366-1374.
18. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative longterm survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63; discussion 63-65.
19. Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997;63:334-338. (Pubitemid 27084548)
20. Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg 1996;224:288-294; discussion 294-296.
21. Sugarbaker DJ, Mentzer SJ, DeCamp M, et al. Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma. Chest 1993;103:377S-381S.
22. Sugarbaker DJ, Heher EC, Lee TH, et al. Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1991;102:10-14; discussion 14-15.
23. Martin-Ucar AE, Nakas A, Edwards JG, et al. Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma. Eur J Cardiothorac Surg 2007;31:765-770; discussion 770-771. (Pubitemid 46528743)
24. Edwards JG, Martin-Ucar AE, Stewart DJ, et al. Right extrapleural pneumonectomy for malignant mesothelioma via median sternotomy or thoracotomy? Short-and long-term results. Eur J Cardiothorac Surg 2007;31:759-764.
25. Edwards JG, Stewart DJ, Martin-Ucar A, et al. The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma. J Thorac Cardiovasc Surg 2006;131: 981-987.
26. Stewart DJ, Martin-Ucar AE, Edwards JG, et al. Extra-pleural pneumonectomy for malignant pleural mesothelioma: the risks of induction chemotherapy, right-sided procedures and prolonged operations. Eur J Cardiothorac Surg 2005;27:373-378.
27. Stewart DJ, Martin-Ucar A, Pilling JE, et al. The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma. Ann Thorac Surg 2004;78:245-252. (Pubitemid 38833940)
28. Norman PH, Thall PF, Purugganan RV, et al. A possible association between aprotinin and improved survival after radical surgery for mesothelioma. Cancer 2009;115:833-841.
29. Arrossi AV, Lin E, Rice D, et al. Histologic assessment and prognostic factors of malignant pleural mesothelioma treated with extrapleural pneumonectomy. Am J Clin Pathol 2008;130:754-764.
30. Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007;84:1685-1692; discussion 1692-1693.
31. Ahamad A, Stevens CW, Smythe WR, et al. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J 2003;9: 476-484. (Pubitemid 44403485)
32. de Perrot M, Feld R, Cho BCJ, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:1413-1418.
33. de Perrot M, McRae K, Anraku M, et al. Risk factors for major complications after extrapleural pneumonectomy for malignant pleural mesothelioma. Ann Thorac Surg 2008;85:1206-1210. (Pubitemid 351381665)
34. de Perrot M, Uy K, Anraku M, et al. Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2007;133:111-116. (Pubitemid 46014196)
35. Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007;18:1196-1202. (Pubitemid 47244366)
36. Opitz I, Kestenholz P, Lardinois D, et al. Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Eur J Cardiothorac Surg 2006;29:579-584.
37. Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004;22:3451-3457. (Pubitemid 41103650)
38. Pompeo E, Albonici L, Doldo E, et al. Placenta growth factor expression has prognostic value in malignant pleural mesothelioma. Ann Thorac Surg 2009;88:426-431.
39. Ambrogi V, Mineo D, Gatti A, et al. Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma. J Surg Oncol 2009;100:199-204.
40. Mineo TC, Ambrogi V, Pompeo E, et al. The value of occult disease in resection margin and lymph node after extrapleural pneumonectomy for malignant mesothelioma. Ann Thorac Surg 2008;85:1740-1746. (Pubitemid 351608195)
41. Yan TD, Boyer M, Tin MM, et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. J Thorac Cardiovasc Surg 2009;138:619-624.
42. Yan TD, Boyer M, Tin MM, et al. Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma. Ann Thorac Surg 2009;87:1552-1556.
43. Hasani A, Alvarez JM, Wyatt JM, et al. Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia. J Thorac Oncol 2009;4:1010-1016.
44. Alvarez JM, Hasani A, Segal A, et al. Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy. ANZ J Surg 2009;79:734-738.
45. van Sandick JW, Kappers I, Baas P, et al. Surgical treatment in the management of malignant pleural mesothelioma: a single institution's experience. Ann Surg Oncol 2008;15:1757-1764.
46. Schouwink H, Rutgers ET, van der Sijp J, et al. Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results. Chest 2001;120: 1167-1174. (Pubitemid 32960089)
47. Pass HI, Temeck BK, Kranda K, et al. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1998;115:310-317;discussion 317-318. (Pubitemid 28093745)
48. Pass HI, Kranda K, Temeck BK, et al. Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol 1997;4:215-222. (Pubitemid 127725247)
49. Trousse DS, Avaro JP, D'Journo XB, et al. Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies. Eur J Cardiothorac Surg 2009;36:759-763.
50. Buduhan G, Menon S, Aye R, et al. Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 2009;88:870-875;discussion 876.
51. Schipper PH, Nichols FC, Thomse KM, et al. Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg 2008;85:257-264; discussion 264.
52. Aigner C, Hoda MA, Lang G, et al. Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. Eu J Cardiothorac Surg 2008;34:204-207.
53. Ribi K, Bernhard J, Schuller JC, et al. Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. Lung Cancer 2008; 61:398-404.
54. Okada M, Mimura T, Ohbayashi C, et al. Radical surgery for malignant pleural mesothelioma: results and prognosis. Interact Cardiovasc Thorac Surg 2008;7:102-106.
55. Batirel HF, Metintas M, Caglar HB, et al. Trimodality treatment of malignant pleural mesothelioma. J Thorac Oncol 2008;3:499-504. (Pubitemid 351630277)
56. Rea F, Marulli G, Bortolotti L, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer 2007;57:89-95. (Pubitemid 46843340)
57. Pagan V, Ceron L, Paccagnella A, et al. 5-year prospective results of trimodality treatment for malignant pleural mesothelioma. J Cardiovasc Surg 2006;47:595-601. (Pubitemid 44696791)
58. de Vries WJ, Long MA. Treatment of mesothelioma in Bloemfontein, South Africa. Eur J Cardiothorac Surg 2003;24:434-440.
59. Aziz T, Jilaihawi A, Prakash D. The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur J Cardiothorac Surg 2002;22:298-305. (Pubitemid 34831874)
60. Maggi G, Casadio C, Cianci R, et al. Trimodality management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2001;19:346-350. (Pubitemid 32197443)
61. Takagi K, Tsuchiya R, Watanabe Y. Surgical approach to pleural diffuse mesothelioma in Japan. Lung Cancer 2001;31:57-65. (Pubitemid 32012603)
62. Branscheid D, Krysa S, Bauer E, et al. Diagnostic and therapeutic strategy in malignant pleural mesothelioma. Eur J Cardiothorac Surg 1991;5:466-472; discussion 473.
63. Faber LP. 1986: extrapleural pneumonectomy for diffuse, malignant mesothelioma. Updated in 1994. Ann Thorac Surg 1994;58:1782-1783.
64. Maziak DE, Gagliardi A, Haynes AE, et al. Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer 2005;48:157-169. (Pubitemid 40501805)
65. Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest 1993;103:373S-376S. (Pubitemid 23110357)
66. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol 1996;14:1007-1017. (Pubitemid 26085549)
67. Lerner HJ, Schoenfeld DA, Martin A, et al. Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1983;52:1981-1985.
68. Zidar BL, Green S, Pierce HI, et al. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest New Drugs 1988;6:223-226.
69. Sarot IA. Extrapleural pneumonectomy and pleurectomy in pulmonary tuberculosis. Thorax 1949;4:173-223.
70. Butchart EG, Ashcroft T, Barnsley WC, et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 1976;31:15-24.
71. Treasure T, Utley M. Ten traps for the unwary in surgical series: a case study in mesothelioma reports. J Thorac Cardiovasc Surg 2007;133: 1414-1418. (Pubitemid 46805160)
72. Treasure T, Swift S, Tan C. Radical surgery for mesothelioma: how can we obtain evidence? World J Surg 2003;27:891-894. (Pubitemid 37051937)
73. Treasure T, Sedrakyan A. Pleural mesothelioma: little evidence, still time to do trials. Lancet 2004;364:1183-1185. (Pubitemid 39296609)
74. Treasure T, Waller D, Tan C, et al. The mesothelioma and radical surgery randomized controlled trial: the MARS feasibility study. J Thorac Oncol 2009;4:1254-1258.